The rise of new drugs in the GLP-1 and GIP analog class, such as Ozempic and Wegovy, is leading to an increase in prescriptions, budgets, and profits for pharmaceutical companies. These drugs offer promise for treating diabetes and obesity, with significant weight loss as a side effect. However, they only treat the effects of these conditions, not the underlying causes. While these drugs may be effective, they are not a substitute for lifestyle changes. Access to comprehensive healthcare services, healthy food options, and support for physical and mental health is crucial for long-term success in managing these conditions.
Source link
Are we losing sight of overall health? Here’s what the science says
